Sign up to save your podcasts
Or
Share Experts Talk CLL #2 : Considerations when Choosing 1L CLL Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #2 : Considerations when Choosing 1L CLL Therapy
A discussion between Dr. Peter Anglin and Dr. Othman Al-Sawaf (Fall 2021)
Dr. Peter Anglin and Dr. Othman Al-Sawaf discuss therapeutic options for newly diagnosed CLL patients – from risk stratification and patient preferences to treatment duration and sequencing considerations. They examine data from clinical trials, review toxicity profiles of various approaches, and contrast the options of being on continuous vs fixed duration therapy from the patient’s and physician’s perspectives.
Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON
Othman AI-Sawaf, MD Hematologist/Oncologist University Hospital of Cologne, Germany Study physician, German CLL Study Group (GCLLSG)
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. Othman Al-Sawaf (Fall 2021)
Dr. Peter Anglin and Dr. Othman Al-Sawaf discuss therapeutic options for newly diagnosed CLL patients – from risk stratification and patient preferences to treatment duration and sequencing considerations. They examine data from clinical trials, review toxicity profiles of various approaches, and contrast the options of being on continuous vs fixed duration therapy from the patient’s and physician’s perspectives.
Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON
Othman AI-Sawaf, MD Hematologist/Oncologist University Hospital of Cologne, Germany Study physician, German CLL Study Group (GCLLSG)
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.